ATE554075T1 - Bei mit mtor-kinase und/oder pi3k in zusammenhang stehenden krankheiten angewendete morpholinopyrimidinderivate - Google Patents

Bei mit mtor-kinase und/oder pi3k in zusammenhang stehenden krankheiten angewendete morpholinopyrimidinderivate

Info

Publication number
ATE554075T1
ATE554075T1 AT08776183T AT08776183T ATE554075T1 AT E554075 T1 ATE554075 T1 AT E554075T1 AT 08776183 T AT08776183 T AT 08776183T AT 08776183 T AT08776183 T AT 08776183T AT E554075 T1 ATE554075 T1 AT E554075T1
Authority
AT
Austria
Prior art keywords
morpholinopyrimidene
pi3k
diseases related
derivatives used
mtor kinase
Prior art date
Application number
AT08776183T
Other languages
German (de)
English (en)
Inventor
Kurt Pike
Original Assignee
Astrazeneca Ab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Astrazeneca Ab filed Critical Astrazeneca Ab
Application granted granted Critical
Publication of ATE554075T1 publication Critical patent/ATE554075T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
    • C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
    • C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
    • C07D239/32—One oxygen, sulfur or nitrogen atom
    • C07D239/42—One nitrogen atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Hematology (AREA)
  • Oncology (AREA)
  • Immunology (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Pulmonology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
AT08776183T 2007-07-09 2008-07-08 Bei mit mtor-kinase und/oder pi3k in zusammenhang stehenden krankheiten angewendete morpholinopyrimidinderivate ATE554075T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US94853907P 2007-07-09 2007-07-09
PCT/GB2008/050548 WO2009007750A1 (en) 2007-07-09 2008-07-08 Morpholino pyrimidine derivatives used in diseases linked to mtor kinase and/or pi3k

Publications (1)

Publication Number Publication Date
ATE554075T1 true ATE554075T1 (de) 2012-05-15

Family

ID=39791229

Family Applications (1)

Application Number Title Priority Date Filing Date
AT08776183T ATE554075T1 (de) 2007-07-09 2008-07-08 Bei mit mtor-kinase und/oder pi3k in zusammenhang stehenden krankheiten angewendete morpholinopyrimidinderivate

Country Status (21)

Country Link
US (1) US8138183B2 (en:Method)
EP (1) EP2176238B1 (en:Method)
JP (1) JP5508260B2 (en:Method)
KR (1) KR20100042280A (en:Method)
CN (1) CN101809002B (en:Method)
AR (1) AR070079A1 (en:Method)
AT (1) ATE554075T1 (en:Method)
AU (1) AU2008273891B2 (en:Method)
BR (1) BRPI0814688A2 (en:Method)
CA (1) CA2692720A1 (en:Method)
CL (1) CL2008003940A1 (en:Method)
CO (1) CO6251364A2 (en:Method)
CR (1) CR11200A (en:Method)
DO (1) DOP2010000012A (en:Method)
EA (1) EA018708B1 (en:Method)
EC (1) ECSP109935A (en:Method)
ES (1) ES2385692T3 (en:Method)
NI (1) NI201000002A (en:Method)
PE (1) PE20100138A1 (en:Method)
WO (1) WO2009007750A1 (en:Method)
ZA (1) ZA200909224B (en:Method)

Families Citing this family (54)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2009007748A2 (en) * 2007-07-09 2009-01-15 Astrazeneca Ab Trisubstituted pyrimidine derivatives for the treatment of proliferative diseases
EP2307400B1 (en) 2008-05-30 2014-04-23 Amgen, Inc Inhibitors of pi3 kinase
CA2755061A1 (en) 2009-03-13 2010-09-16 Cellzome Limited Pyrimidine derivatives as mtor inhibitors
UY32582A (es) 2009-04-28 2010-11-30 Amgen Inc Inhibidores de fosfoinositida 3 cinasa y/u objetivo mamífero
KR20120106714A (ko) 2009-07-02 2012-09-26 사노피 신규 (6-옥소-1,6-디히드로-피리미딘-2-일)아미드 유도체, 그의 제조법, 및 ａｋｔ(ｐｋｂ) 인산화 억제제로서의 그의 제약 용도
EP2448932B1 (fr) 2009-07-02 2014-03-05 Sanofi Nouveaux derives de 6-morpholin-4-yl-pyrimidin-4-(3h)-one, leur preparation pharmaceutique comme inhibiteurs de phosphorylation d'akt(pkb)
US20120316137A1 (en) 2009-10-30 2012-12-13 Ariad Pharmaceuticals, Inc. Methods and Compositions for Treating Cancer
JP6114554B2 (ja) 2010-02-03 2017-04-12 シグナル ファーマシューティカルズ，エルエルシー Ｔｏｒキナーゼ阻害剤に対する感受性についての予測的なバイオマーカーとしてのｌｋｂ１変異の同定
ES2535116T3 (es) 2010-03-04 2015-05-05 Cellzome Limited Derivados de urea sustituida con morfolino como inhibidores de mtor
JO2998B1 (ar) 2010-06-04 2016-09-05 Amgen Inc مشتقات بيبيريدينون كمثبطات mdm2 لعلاج السرطان
EP2658844B1 (fr) 2010-12-28 2016-10-26 Sanofi Nouveaux derives de pyrimidines, leur preparation et leur utilisation pharmaceutique comme inhibiteurs de phosphorylation d'akt(pkb)
JP2014510122A (ja) 2011-04-04 2014-04-24 セルゾーム リミテッド ｍＴＯＲ阻害剤としてのジヒドロピロロピリミジン誘導体
EA201790045A1 (ru) 2011-04-29 2017-09-29 Селекта Байосайенсиз, Инк. Наноносители, вырабатывающие имунную толерантность, для антиген-специфического удаления т-эффекторных клеток
AU2012290056B2 (en) 2011-08-03 2015-03-19 Signal Pharmaceuticals, Llc Identification of gene expression profile as a predictive biomarker for LKB1 status
CA2849189A1 (en) 2011-09-21 2013-03-28 Cellzome Limited Morpholino substituted urea or carbamate derivatives as mtor inhibitors
WO2013049250A1 (en) 2011-09-27 2013-04-04 Amgen Inc. Heterocyclic compounds as mdm2 inhibitors for the treatment of cancer
BR112014008241A2 (pt) 2011-10-07 2017-04-18 Cellzome Ltd composto, composição farmacêutica, métodos para tratar, controlar, retardar ou prevenir doenças e distúrbios, e para preparar um composto, e, uso de um composto
RU2684595C2 (ru) 2012-07-04 2019-04-09 Ф.Хоффманн-Ля Рош Аг Ковалентно связанные конъюгаты антиген-антитело
FR2994572B1 (fr) * 2012-08-17 2015-04-17 Centre Nat Rech Scient Pyrido[3,2-d]pyrimidines trisubstituees, leurs procedes de preparation et leurs utilisation en therapeutique
AU2013203714B2 (en) 2012-10-18 2015-12-03 Signal Pharmaceuticals, Llc Inhibition of phosphorylation of PRAS40, GSK3-beta or P70S6K1 as a marker for TOR kinase inhibitory activity
US11407721B2 (en) 2013-02-19 2022-08-09 Amgen Inc. CIS-morpholinone and other compounds as MDM2 inhibitors for the treatment of cancer
JP6417338B2 (ja) * 2013-02-19 2018-11-07 アムジエン・インコーポレーテツド 癌の治療のためのｍｄｍ２阻害剤としてのシス−モルホリノン及び他の化合物
MX374513B (es) 2013-03-14 2025-03-06 Amgen Inc Compuestos de morfolinona de ácido heteroarilo como inhibidores mdm2 para el tratamiento de cáncer.
EP2986319A1 (en) 2013-04-17 2016-02-24 Signal Pharmaceuticals, LLC Combination therapy comprising a tor kinase inhibitor and n-(3-(5-fluoro-2-(4-(2-methoxyethoxy)phenylamino)pyrimidin-4-ylamino)phenyl)acrylamide for treating cancer
JP6382949B2 (ja) 2013-04-17 2018-08-29 シグナル ファーマシューティカルズ，エルエルシー 癌を治療するためのｔｏｒキナーゼ阻害剤及び５−置換キナゾリノン化合物を含む組合せ療法
HK1221150A1 (zh) 2013-04-17 2017-05-26 西格诺药品有限公司 用二氢吡嗪并-吡嗪类对癌症的治疗
SG11201508223YA (en) 2013-04-17 2015-11-27 Signal Pharm Llc Treatment of cancer with dihydropyrazino-pyrazines
EP3549940A1 (en) 2013-04-17 2019-10-09 Signal Pharmaceuticals, LLC Pharmaceutical formulations, of 1-ethyl-7-(2-methyl-6-(1h-1,2,4-triazol-3-yl) pyridin-3-yl) -3,4-dihydropyrazino[2,3-b]pyrazin-2(1h)-one
WO2014172431A1 (en) 2013-04-17 2014-10-23 Signal Pharmaceuticals, Llc Combination therapy comprising a dihydropyrazino-pyrazine compound and an androgen receptor antagonist for treating prostate cancer
US9782427B2 (en) 2013-04-17 2017-10-10 Signal Pharmaceuticals, Llc Methods for treating cancer using TOR kinase inhibitor combination therapy
EP2991631A4 (en) 2013-05-03 2016-11-16 Selecta Biosciences Inc TOLEROGENIC SYNTHETIC NANOTRANS AND THERAPEUTIC MACROMOLECULES FOR REDUCED OR IMPROVED PHARMACODYNAMIC EFFECTS
US9604939B2 (en) 2013-05-29 2017-03-28 Signal Pharmaceuticals, Llc Pharmaceutical compositions of 7-(6-(2-hydroxypropan-2-YL)pyridin-3-YL)-1-((trans)-4-methoxycyclohexyl)-3,4-dihydropyrazino [2,3-B]pyrazin-2(1H)-one, a solid form thereof and methods of their use
JOP20200296A1 (ar) 2013-06-10 2017-06-16 Amgen Inc عمليات صنع وأشكال بلورية من mdm2 مثبط
WO2015101586A1 (en) 2014-01-03 2015-07-09 F. Hoffmann-La Roche Ag Bispecific anti-hapten/anti-blood brain barrier receptor antibodies, complexes thereof and their use as blood brain barrier shuttles
JP2017511367A (ja) 2014-04-16 2017-04-20 シグナル ファーマシューティカルズ，エルエルシー １−エチル−７−（２−メチル−６−（１Ｈ−１，２，４−トリアゾール−３−イル）ピリジン−３−イル）−３，４−ジヒドロピラジノ［２，３−ｂ］ピラジン−２（１Ｈ）−オン及び共形成物を含む固体形態、その組成物及び使用方法
NZ714742A (en) 2014-04-16 2017-04-28 Signal Pharm Llc Solid forms of 1-ethyl-7-(2-methyl-6-(1h-1,2,4-triazol-3-yl)pyridin-3-yl)-3,4-dihydropyrazino[2,3-b]pyrazin-2(1h)-one, compositions thereof and methods of their use
EP3164419B1 (en) 2014-06-26 2024-07-24 F. Hoffmann-La Roche AG Anti-brdu antibodies and methods of use
RS63190B1 (sr) 2014-08-04 2022-06-30 Nuevolution As Opciono fuzionisani derivati pirimidina zamenjeni heterociklilom korisni za lečenje zapaljenskih, metaboličkih, onkoloških i autoimunskih bolesti
BR112017001311A2 (pt) 2014-09-07 2017-11-14 Selecta Biosciences Inc métodos e composições para atenuar as respostas imunes do vetor de transferência anti-viral de salto de éxon
TW201813963A (zh) 2016-09-23 2018-04-16 美商基利科學股份有限公司 磷脂醯肌醇3-激酶抑制劑
TW201825465A (zh) 2016-09-23 2018-07-16 美商基利科學股份有限公司 磷脂醯肌醇3-激酶抑制劑
TW201815787A (zh) 2016-09-23 2018-05-01 美商基利科學股份有限公司 磷脂醯肌醇3-激酶抑制劑
AU2018236123B2 (en) 2017-03-11 2024-04-18 Selecta Biosciences, Inc. Methods and compositions related to combined treatment with anti-inflammatories and synthetic nanocarriers comprising an immunosuppressant
WO2018218197A2 (en) 2017-05-26 2018-11-29 Board Of Regents, The University Of Texas System Tetrahydropyrido[4,3-d]pyrimidine inhibitors of atr kinase
MY198676A (en) 2017-06-22 2023-09-15 Celgene Corp Treatment of hepatocellular carcinoma characterized by hepatitis b virus infection
WO2019014618A1 (en) 2017-07-13 2019-01-17 Board Of Regents, University Of Texas System HETEROCYCLIC INHIBITORS OF KINASE ATR
WO2019036641A1 (en) 2017-08-17 2019-02-21 Board Of Regents, The University Of Texas System HETEROCYCLIC INHIBITORS OF KINASE ATR
WO2019178590A1 (en) 2018-03-16 2019-09-19 Board Of Regents, The University Of Texas System Heterocyclic inhibitors of atr kinase
AU2020405446A1 (en) 2019-12-20 2022-05-26 Nuevolution A/S Compounds active towards nuclear receptors
US11685727B2 (en) 2019-12-20 2023-06-27 Nuevolution A/S Compounds active towards nuclear receptors
EP4126875A1 (en) 2020-03-31 2023-02-08 Nuevolution A/S Compounds active towards nuclear receptors
MX2022012260A (es) 2020-03-31 2022-11-30 Nuevolution As Compuestos activos frente a receptores nucleares.
CN111646985A (zh) * 2020-06-01 2020-09-11 江苏集萃分子工程研究院有限公司 一种含嘧啶杂环抗肿瘤药物分子azd6738的合成方法
TW202337494A (zh) 2021-11-16 2023-10-01 美商建南德克公司 用莫蘇妥珠單抗治療全身性紅斑狼瘡（ｓｌｅ）之方法及組成物

Family Cites Families (46)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE3922735A1 (de) 1989-07-11 1991-01-24 Hoechst Ag Aminopyrimidin-derivate, verfahren zu ihrer herstellung, sie enthaltende mittel und ihre verwendung als fungizide
CN1186324C (zh) 2000-04-27 2005-01-26 山之内制药株式会社 稠合杂芳基衍生物
JP3810017B2 (ja) * 2000-04-27 2006-08-16 アステラス製薬株式会社 縮合ヘテロアリール誘導体
JP2004524279A (ja) * 2000-11-10 2004-08-12 エフ．ホフマン−ラ　ロシュ　アーゲー ピリミジン誘導体、及びニューロペプチドｙ受容体リガンドとしてのその使用
US7423148B2 (en) 2002-11-21 2008-09-09 Chiron Corporation Small molecule PI 3-kinase inhibitors and methods of their use
JP2007500241A (ja) 2003-05-29 2007-01-11 シンタ ファーマシューティカルズ コーポレーション 過度の骨量減少に関連する疾患の予防及び治療用の複素環化合物
GB0415364D0 (en) * 2004-07-09 2004-08-11 Astrazeneca Ab Pyrimidine derivatives
GB0415367D0 (en) 2004-07-09 2004-08-11 Astrazeneca Ab Pyrimidine derivatives
GB0415365D0 (en) * 2004-07-09 2004-08-11 Astrazeneca Ab Pyrimidine derivatives
WO2007084413A2 (en) 2004-07-14 2007-07-26 Ptc Therapeutics, Inc. Methods for treating hepatitis c
US7772271B2 (en) * 2004-07-14 2010-08-10 Ptc Therapeutics, Inc. Methods for treating hepatitis C
US7696202B2 (en) * 2004-11-10 2010-04-13 Synta Pharmaceuticals Corp. IL-12 modulatory compounds
WO2006124874A2 (en) 2005-05-12 2006-11-23 Kalypsys, Inc. Inhibitors of b-raf kinase
WO2006124662A1 (en) 2005-05-13 2006-11-23 Synta Pharmaceuticals Corp. Il-12 modulatory compounds
NZ563774A (en) 2005-05-20 2010-04-30 Methylgene Inc Inhibitors of VEGF receptor and HGF receptor signaling
DE102005024494A1 (de) 2005-05-27 2006-11-30 Bayer Healthcare Ag Verwendung von Cyanopyrimidinen
AU2006265840B2 (en) 2005-07-01 2010-02-11 Irm Llc Pyrimidine-substituted benzimidazole derivatives as protein kinase inhibitors
WO2007013691A1 (ja) 2005-07-29 2007-02-01 Takeda Pharmaceutical Company Limited スピロ環化合物
KR20080052630A (ko) * 2005-09-01 2008-06-11 어레이 바이오파마 인크. Ｒａｆ 억제제 화합물 및 그의 사용 방법
JP2007091649A (ja) 2005-09-29 2007-04-12 Taisho Pharmaceut Co Ltd ピリミジン誘導体及びその使用に関連する治療方法
JP4531027B2 (ja) 2005-09-29 2010-08-25 田辺三菱製薬株式会社 医薬組成物
AU2006297351A1 (en) 2005-09-30 2007-04-12 Vertex Pharmaceuticals Incorporated Deazapurines useful as inhibitors of janus kinases
BRPI0616630B8 (pt) 2005-09-30 2021-05-25 Miikana Therapeutics Inc compostos de pirazol substituídos
GB2431156A (en) 2005-10-11 2007-04-18 Piramed Ltd 1-cyclyl-3-substituted- -benzenes and -azines as inhibitors of phosphatidylinositol 3-kinase
GB0520657D0 (en) 2005-10-11 2005-11-16 Ludwig Inst Cancer Res Pharmaceutical compounds
TW200800963A (en) 2005-10-28 2008-01-01 Astrazeneca Ab Chemical compounds
CA2636314A1 (en) 2005-11-29 2007-06-07 Toray Industries, Inc. Arylmethylene urea derivative and use thereof
GB0525083D0 (en) 2005-12-09 2006-01-18 Astrazeneca Ab Pyrimidine derivatives
GB0525081D0 (en) 2005-12-09 2006-01-18 Astrazeneca Ab Pyrimidine derivatives
GB0525080D0 (en) 2005-12-09 2006-01-18 Astrazeneca Ab Pyrimidine derivatives
NL2000323C2 (nl) 2005-12-20 2007-11-20 Pfizer Ltd Pyrimidine-derivaten.
BRPI0706395A2 (pt) * 2006-01-11 2011-03-22 Astrazeneca Ab composto, uso do mesmo, métodos para produzir um efeito anti-proliferativo em um animal de sangue quente e para tratar doença, composição farmacêutica, e, processo para preparar um composto
JO2660B1 (en) 2006-01-20 2012-06-17 نوفارتيس ايه جي Pi-3 inhibitors and methods of use
US8440663B2 (en) 2006-01-30 2013-05-14 Exelixis, Inc. 4-aryl-2-amino-pyrimidines or 4-aryl-2-aminoalkyl-pyrimidines as JAK-2 modulators and methods of use
CN101438288A (zh) 2006-03-15 2009-05-20 Csir公司 谷氨酰胺合成酶的磷酰基转移酶活性的调节
JP5243696B2 (ja) 2006-03-17 2013-07-24 田辺三菱製薬株式会社 ベンゼン誘導体
WO2007114323A1 (ja) 2006-04-04 2007-10-11 Taisho Pharmaceutical Co., Ltd. アミノピロリジン化合物
CN101472915A (zh) 2006-04-19 2009-07-01 诺瓦提斯公司 吲唑化合物和抑制cdc7的方法
JP5225076B2 (ja) 2006-04-27 2013-07-03 田辺三菱製薬株式会社 チアゾール環を含むカルボン酸誘導体の医薬用途
GB0610909D0 (en) 2006-06-05 2006-07-12 Merck Sharp & Dohme Therapeutic treatment
CA2656290A1 (en) 2006-07-05 2008-01-10 Exelixis, Inc. Methods of using igf1r and abl kinase modulators
WO2008023159A1 (en) * 2006-08-24 2008-02-28 Astrazeneca Ab Morpholino pyrimidine derivatives useful in the treatment of proliferative disorders
US20090325957A1 (en) * 2006-08-24 2009-12-31 Astrazeneca Ab Morpholino pyrimidine derivatives useful in the treatment of proliferative disorders
US20080234262A1 (en) * 2007-03-21 2008-09-25 Wyeth Pyrazolopyrimidine analogs and their use as mtor kinase and pi3 kinase inhibitors
US20100256143A1 (en) 2007-04-12 2010-10-07 Stewart James Baker Pharmaceutical compounds
AU2008273892A1 (en) 2007-07-09 2009-01-15 Astrazeneca Ab Trisubstituted pyrimidine derivatives for the treatment of proliferative diseases

Also Published As

Publication number Publication date
EA018708B1 (ru) 2013-10-30
PE20100138A1 (es) 2010-03-20
EP2176238B1 (en) 2012-04-18
DOP2010000012A (es) 2010-01-31
WO2009007750A1 (en) 2009-01-15
CN101809002B (zh) 2013-03-27
CR11200A (es) 2010-06-17
KR20100042280A (ko) 2010-04-23
CA2692720A1 (en) 2009-01-15
AU2008273891A1 (en) 2009-01-15
CL2008003940A1 (es) 2010-09-24
JP2010533160A (ja) 2010-10-21
US8138183B2 (en) 2012-03-20
JP5508260B2 (ja) 2014-05-28
EP2176238A1 (en) 2010-04-21
HK1142906A1 (en) 2010-12-17
BRPI0814688A2 (pt) 2017-06-06
EA201000091A1 (ru) 2010-06-30
AR070079A1 (es) 2010-03-10
NI201000002A (es) 2010-10-12
AU2008273891B2 (en) 2012-01-12
CO6251364A2 (es) 2011-02-21
ES2385692T3 (es) 2012-07-30
ZA200909224B (en) 2011-05-25
ECSP109935A (es) 2010-03-31
CN101809002A (zh) 2010-08-18
US20100249131A1 (en) 2010-09-30

Similar Documents

Publication Publication Date Title
ATE554075T1 (de) Bei mit mtor-kinase und/oder pi3k in zusammenhang stehenden krankheiten angewendete morpholinopyrimidinderivate
IL232256A0 (en) Novel purine derivatives and their use in the treatment of disease
ZA201100845B (en) Purine derivatives for use in the treatment of allergic,inflammatory and infectious diseases
ZA201101105B (en) Purine derivatives for use in the treatment of allergic,inflammatory and infectious diseases
ZA201000075B (en) Purin derivatives for use in the treatment of fab-related diseases
IL193230A (en) Use of benzoxoborol derivatives in the preparation of drugs for the treatment of inflammatory diseases
BRPI0811353A2 (pt) Corpo em camadas de membros do tipo-folha
BR112012031194A2 (pt) derivados de cisteamina e seu uso no tratamento de ehna
BRPI1011066A2 (pt) "pirazolopirimidinas e heterociclos relacionados como inibidores de quinase
DK2483278T3 (da) Benzoxazepin pi3k-inhibitorforbindelser og deres anvendelse i behandlingen af cancer
ATE472546T1 (de) 5-heteroarylthiazole und deren verwendung als pi3k-inhibitoren
EP2406262A4 (en) PRODRUG FORMS OF KINASEHEMMERN AND THEIR USE IN THERAPY
IL210802A0 (en) Purin derivatives for use in the treatment of fab-related diseases
BRPI0810094A2 (pt) Inibidores de kinase úteis para o tratamento de doenças mieloproliferativas e outras doenças proliferativas
DE602008001981D1 (de) Stellung und therapeutische verwendung
SI2046324T1 (sl) Zdravljenje in preventiva mukozitisa z derivati antocianidina
IL195900A0 (en) Piperazinyl derivatives useful in the treatment of gpr38 receptor mediated diseases
IL206690A0 (en) Protein kinase inhibitors and their use in the preparation of medicaments
DK3211005T3 (da) Terapeutisk anvendelse af specifik ligand i msrv-associerede sygdomme
BRPI0717774A2 (pt) Tratamento de hiperbilirrubinemia em recém-nascidos que utiliza baixas dosagens de estansoporfina
SI2170877T1 (sl) Substutuirani (oksazolidinon-5-il-metil)-2-tiofen-karboksamidi in njihova uporaba na področju koagulacije krvi
BRPI0817044A2 (pt) Compostos de nicotinamida substituída e seu uso em medicamentos
BRPI0714318A2 (pt) Utilização de 2-benzoil-imidazopiridinas em terapêutica
DK2293846T3 (da) Depsipeptider og deres terapeutiske anvendelse
EP2170394A4 (en) T REGULATORY LYMPHOCYTES IN ADIPOSE TISSUE